Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs

European Journal of Medicinal Chemistry

Volumn 46, Issue 7, 2011, Pages 2867-2879

  Daumar, Pierre ^a,b   Decombat, Caroline ^a   Chezal, Jean Michel ^a,b   Debiton, Eric ^a,b   Madesclaire, Michel ^a   Coudert, Pascal ^a,b   Galmier, Marie Josphe ^a,b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

Author keywords

2 Fluoro 2 deoxy d glucose derivatives; 5 Fluorouracil (5 FU); Anti cancer prodrugs; Chimaeric prodrugs; HPLC; Prodrug stability

Indexed keywords

1 (2 FLUORO 2 DEOXY BETA DEXTRO GLUCOPYRANOSYL) 5 FLUOROURACIL; 1 (3,4,6 TRI O ACETYL 2 FLUORO 2 DEOXY BETA DEXTRO GLUCOPYRANOSYL) 5 FLUOROURACIL; 1 [N [2 (3,4,6 TRI O ACETYL 2 FLUORO 2 DEOXY BETA DEXTRO GLUCOPYRANOSYL)AMINO 2 OXOBUTYL] N' METHYLCARBAMOYL] 5 FLUOROURACIL; 1 [N [2 (3,4,6 TRI O ACETYL 2 FLUORO 2 DEOXY BETA DEXTRO GLUCOPYRANOSYL)AMINO 2 OXOBUTYL]CARBAMOYL] 5 FLUOROURACIL; 1 [N [2 (3,4,6 TRI O ACETYL 2 FLUORO 2 DEOXY BETA DEXTRO GLUCOPYRANOSYL)AMINO 2 OXOETHYL]CARBAMOYL] 5 FLUOROURACIL; 1 [N [2 (3,4,6 TRI O ACETYL 2 FLUORO 2 DEOXY BETA DEXTRO GLUCOPYRANOSYL)AMINO 2 OXOHEXYL]CARBAMOYL] 5 FLUOROURACIL; 1 [N [2 (3,4,6 TRI O ACETYL 2 FLUORO 2 DEOXY BETA DEXTRO GLUCOPYRANOSYLOXYL)PHENYL N METHYL]CARBAMOYL 5 FLUOROURACIL; FLUORODEOXYGLUCOSE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; N (3,4,6 TRI O ACETYL 2 FLUORO 2 DEOXY BETA DEXTRO GLUCOPYRANOSYL) 2 (5 FLUOROURACIL 1 YL)ACETAMIDE; PRODRUG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; FLUORODEOXYGLUCOSE F 18;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG DEGRADATION; DRUG DESIGN; DRUG HALF LIFE; DRUG RELEASE; DRUG SENSITIVITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; BLOOD; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HALF LIFE TIME; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; DRUG LIBERATION; DRUG STABILITY; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HALF-LIFE; HUMANS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79957475688     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.04.010     Document Type: Article

References (38)

1. C. Heidelberger, N.K. Chaudhuri, P. Danneberg, D. Mooren, L. Griesbach, R. Duschinsky, R.J. Schnitzer, E. Pleven, and J. Scheiner Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
2. F. Tanaka, T. Fukuse, H. Wada, and M. Fukushima The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents Curr. Pharm. Biotechnol. 1 2000 137 164
3. D.B. Longley, D.P. Harkin, and P.G. Johnston 5-fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 3 2003 330 338 (Pubitemid 37328853)
4. M. Malet-Martino, P. Jolimaitre, and R. Martino The prodrugs of 5-fluorouracil Curr. Med. Chem. Anticanc Agents 2 2002 267 310 (Pubitemid 34649876)
5. M. Miwa, M. Ura, M. Nishida, N. Sawada, T. Ishikawa, K. Mori, N. Shimma, I. Umeda, and H. Ishitsuka Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur. J. Cancer 34 1998 1274 1281 (Pubitemid 28342121)
6. C.M. Walko, and C. Lindley Capecitabine: a review Clin. Ther. 27 2005 23 44 (Pubitemid 40347299)
7. W.A. Denny Prodrug strategies in cancer therapy Eur. J. Med. Chem. 36 2001 577 595 (Pubitemid 32964730)
8. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2 2002 750 763 (Pubitemid 37328910)
9. S. Jaracz, J. Chen, L.V. Kuznetsova, and I. Ojima Recent advances in tumor-targeting anticancer drug conjugates Bioorg. Med. Chem. 13 2005 5043 5054 (Pubitemid 41039965)
10. J.T.C. Wojtyk, R. Goyan, E. Gudgin-Dickson, and R. Pottier Exploiting tumour biology to develop novel drug delivery strategies for PDT Med. Laser Appl. 21 2006 225 238 (Pubitemid 44740537)
11. T. Ganesh Improved biochemical strategies for targeted delivery of taxoids Bioorg. Med. Chem. 15 2007 3597 3623 (Pubitemid 46635143)
12. Z. Liu, and S. Rimmer Synthesis and release of 5-fluorouracil from poly(N-vinylpyrrolidinone) bearing 5-fluorouracil derivatives J. Control Release 81 2002 91 99 (Pubitemid 34460571)
13. R. Madec-Lougerstay, J.-C. Florent, and C. Monneret Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy J. Chem. Soc. Perkin Trans. 1 1999 1369 1376
14. R.M. Phelan, M. Ostermeier, and C.A. Townsend Design and synthesis of a beta-lactamase activated 5-fluorouracil prodrug Bioorg. Med. Chem. Lett. 19 2009 1261 1263
15. M. Rapp, I. Giraud, J.C. Maurizis, M.J. Galmier, and J.C. Madelmont Synthesis and in vivo biodisposition of [14C]-quaternary ammonium-melphalan conjugate, a potential cartilage-targeted alkylating drug Bioconjug. Chem. 14 2003 500 506 (Pubitemid 36348675)
16. M. Rapp, J.C. Maurizis, J. Papon, P. Labarre, T.D. Wu, A. Croisy, J.L. Guerquin-Kern, J.C. Madelmont, and E. Mounetou A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models J. Pharmacol. Exp. Ther. 326 2008 171 177 (Pubitemid 351872125)
17. J.M. Chezal, J. Papon, P. Labarre, C. Lartigue, M.J. Galmier, C. Decombat, O. Chavignon, J. Maublant, J.C. Teulade, J.C. Madelmont, and N. Moins Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl) -4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma J. Med. Chem. 51 2008 3133 3144 (Pubitemid 351821874)
18. B. Reux, V. Weber, M.J. Galmier, M. Borel, M. Madesclaire, J.C. Madelmont, E. Debiton, and P. Coudert Synthesis and cytotoxic properties of new fluorodeoxyglucose-coupled chlorambucil derivatives Bioorg. Med. Chem. 16 2008 5004 5020 (Pubitemid 351635770)
19. E. Miot-Noirault, B. Reux, E. Debiton, J.-C. Madelmont, J.-M. Chezal, P. Coudert, and V. Weber Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents Invest. New Drugs 2009 1 10
20. S.M. Courtney, Therapeutic compounds with pyrimidines base, PCT/GB96/012519, 1999.
21. P. Yin, M.-L. Hu, and L.-C. Hu Synthesis, structural characterization and anticarcinogenic activity of a new Gly-Gly dipeptide derivative: methyl 2-(2-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamido)acetate J. Mol. Struct. 882 2008 75 79 (Pubitemid 351749650)
22. S. Ozaki, Y. Ike, H. Mizuno, K. Ishikawa, and H. Mori 5-Fluorouracil derivatives. I. The synthesis of 1-carbamoyl-5-fluorouracils Bull. Chem. Soc. Jpn. 45 1977 1372 1375
23. S. Ozaki Synthesis and antitumor activity of 5-fluorouracil derivatives Med. Res. Rev. 16 1996 51 86 (Pubitemid 26037076)
24. S. Ozaki, X. Kong, Y. Watanabe, T. Hoshiko, T. Koga, T. Ogasawara, T. Takizawa, H. Fujisawa, M. Iigo, and A. Hoshi 5-Fluorouracil derivatives. XXII. Synthesis and antitumor activities of 1-carbamoyl-5-fluorouracils Chem. Pharm. Bull. 45 1997 1372 1375 (Pubitemid 27382738)
25. A. Buur, and H. Bundgaard Prodrugs of 5-fluorouracil. III. Hydrolysis kinetics in aqueous solution and biological media, lipophilicity and solubility of various 1-carbamoyl derivatives of 5-fluorouracil Int. J. Pharm. 23 1985 209 222 (Pubitemid 15127905)
26. Y. Suda, K. Shimidzu, M. Sumi, N. Oku, S. Kusumoto, T. Nadai, and S. Yamashita The synthesis and in vitro and in vivo stability of 5-fluorouracil prodrugs which possess serum albumin binding potency Biol. Pharm. Bull. 16 1993 876 878 (Pubitemid 23329797)
27. N. Oku, S. Yamashita, N. Sakuragi, K. Doi, S. Okada, K. Shimidzu, M. Sumi, T. Nadai, S. Kusumoto, and Y. Suda Therapeutic efficacy of 5-fluorouracil prodrugs using endogenous serum proteins as drug carriers: a new strategy in drug delivery system Biol. Pharm. Bull. 18 1995 181 184
28. H. Vorbrüggen, K. Krolikiewicz, and B. Bennua Nucleosides syntheses, XXII. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts Chem. Ber. 114 1981 1234 1255
29. G. Zemplén Abbau der reduzierenden Biosen I.: Direk Konstitutions-ermittlung der cellobiose Ber. Dtsch. Chem. Ges. 59B 1926 1254 1260
30. G. Zemplén Abbau der reduzierenden Biosen, VII.: Konstitutions-Ermittlung der Maltose Ber. Dtsch. Chem. Ges. 60B 1927 1555 1564
31. C. Ausin, J.A. Ortega, J. Robles, A. Grandas, and E. Pedroso Synthesis of amino- and guanidino-G-clamp PNA monomers Org. Lett. 4 2002 4073 4075
32. L. Cotarca, P. Delogu, A. Nardelli, and V. Sunnjic Bis(trichloromethyl) carbonate in organic synthesis Synthesis 5 1996 553 576 (Pubitemid 26173728)
33. C. Grandjean, A. Boutonnier, C. Guerreiro, J.M. Fournier, and L.A. Mulard On the preparation of carbohydrate-protein conjugates using the traceless Staudinger ligation J. Org. Chem. 70 2005 7123 7132 (Pubitemid 41233250)
34. J.R. McDermott, and N.L. Benoiton N-Methylamino acids in peptide synthesis. II. A new synthesis of N-Benzyloxycarbonyl, N-Methylamino acids Can. J. Chem. 51 1973 1915 1919
35. D.A. Evans, S. Mito, and D. Seidel Scope and mechanism of enantioselective Michael additions of 1,3-dicarbonyl compounds to nitroalkenes catalyzed by nickel(II)-diamine complexes J. Am. Chem. Soc. 129 2007 11583 11592 (Pubitemid 47555577)
36. J.H. Shah, S. Izenwasser, B. Geter-Douglass, J.M. Witkin, and A.H. Newman (+/-)-(N-alkylamino)benzazepine analogs: novel dopamine D1 receptor antagonists J. Med. Chem. 38 1995 4284 4293
37. Y. Aramaki, M. Seto, T. Okawa, T. Oda, N. Kanzaki, and M. Shiraishi Synthesis of 1-benzothiepine and 1-benzazepine derivatives as orally active CCR5 antagonists Chem. Pharm. Bull. 52 2004 254 258 (Pubitemid 41656760)
38. M. Sassatelli, É Debiton, B. Aboab, M. Prudhomme, and P. Moreau Synthesis and antiproliferative activities of indolin-2-one derivatives bearing amino acid moieties Eur. J. Med. Chem. 41 2006 709 716 (Pubitemid 43866307)